Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French multiinstitutional study

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1697-1703

  Tartour, E ^a   Blay, J Y ^a   Dorval, T ^a   Escudier, B ^a   Mosseri, V ^a   Douillard, J Y ^a   Deneux, L ^a   Gorin, I ^a   Negrier, S ^a   Mathiot, C ^a   Pouillart, P ^a   Fridman, W H ^a  

^a French Cancer Centers' Immunotherapy Group   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; C REACTIVE PROTEIN; CISPLATIN; INTERLEUKIN 2; INTERLEUKIN 6; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FRANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 9244249813     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1697     Document Type: Article

References (51)

1. Everson TC, Cole WH: Spontaneous regression of cancer. Preliminary report. Ann Surg 144:366-380, 1956
2. Mackensen A, Carcelain G, Viel S, et al: Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 93:1397-1402, 1994
3. Dillman RO, Church C, Oldham RK, et al: Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. Cancer 71:2358-2370, 1993
4. Rosenberg SA: The immunotherapy and gene therapy of cancer J Clin Oncol 10:180-199, 1992
5. Tartour E, Mathiot C, Fridman WH: Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 46:1-12, 1992
6. Mule JJ, Yang JC, Lafreniere R, et al: Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant interleukin 2. J Immunol 139:285-294, 1987
7. West WH, Tauer KW, Yanelli JR, et al: Constant infusion recombinant interleukin 2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905, 1987
8. Hanninen EL, Körfer A, Hadam M, et al: Biological monitoring of low dose interleukin 2 in humans: Soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res 50:6312-6316, 1991
9. Kradin RL, Kurnick JT, Lazarus DS, et al: Tumor infiltrating lymphocytes and interleukin 2 in treatment of advanced cancer. Lancet 1:577-580, 1989
10. Favrot MC, Combaret V, Negrier S, et al: Functional and immunophenotypic modifications induced by IL2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Resp Modif 9:167-177, 1990
11. Boldt DH, Mills BJ, Gemlo BT, et al: Laboratory correlates of adoptive immunotherapy with recombinant IL2 and lymphokine-activated killer cells in humans. Cancer Res 48:4409-4416, 1988
12. Gosch AK, Dazzi H, Thatcher N, et al: Correlation between peripheral blood lymphokine activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. Int J Cancer 43:410-414, 1989
13. Schwartzentruber DJ: In vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy. Curr Opin Oncol 5:1055-1058, 1993
14. Dorval T, Mathiot C, Brandely M, et al: IL2 phase II trial in metastatic melanoma. Analysis of clinical and immunological parameters. Biotechnol Ther 3:63-79, 1992
15. Marincola FM, Venzon D, White D, et al: HLA association with response and toxicity in melanoma patients treated with interleukin-2 based immunotherapy. Cancer Res 52:6561-6566, 1992
16. Rubin J, Elwood LJ, Rosenberg SA, et al: Immunohistochemicai correlates of response to recombinant interleukin 2 based immunotherapy in humans. Cancer Res 49:7086-7092, 1989
17. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86:1159-1166, 1994
18. Blay JY, Negrier S, Combaret V, et al: Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL2. Correlation with clinical response to treatment. Bull Cancer 79:55-65, 1992
19. Heslop HE, Gottlieb DJ, Bianchi ACM, et al: In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 74:1374-1380, 1989
20. Kishimoto T, Akira S, Taga T: Interleukin 6 and its receptor: A paradigm for cytokines. Science 258:593-597, 1992
21. Lu C, Kerbel RS: Interleukin 6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120:1281-1288, 1993
22. Tartour E, Dorval T, Mosseri V, et al: Serum interleukin 6 and C reactive protein levels correlate with resistance to IL2 therapy and poor survival in melanoma patients. Br J Cancer 69:911-913, 1994
23. Dorval T, Chevreau C, Baume D, et al: Results of a French multicentric randomized trial of chemoimmunotherapy (cisplatin (P) IL-2 (Proleukin) with or without IFN (ROFERON) in metastatic malignant melanoma. Proc Am Soc Clin Oncol 13:395, 1994 (abstr 1347)
24. Koh HK: Cutaneous melanoma. N Engl J Med 325:171-182, 1991
25. Markowitz JS, Cosimi LA, Carey RW, et al: Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 126:703-708, 1991
26. Balch CM, Soog SJ, Murad TM, et al: A multifactorial analysis of melanoma. IV prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1:126-134, 1983
27. Sirott MN, Bajorin DF, Wong GYC, et al: prognostic factors in patients with metastatic malignant melanoma Cancer 72:3091-3098, 1993
28. Heimdal K, Hannisdal E, Gundersen S: Metastatic malignant melanoma. Eur J Cancer 25:1219-1223, 1989
29. Barth A, Wanek LA, Morton DL: Analysis of prognostic factors in 1521 patients with metastatic melanoma. Proc Am Soc Clin Oncol 14:410, 1995 (abstr 1299)
30. Blay JY, Negrier S, Combaret V, et al: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317-3322, 1992
31. Broom J, Heys SD, Whiting PH, et al: Interleukin 2 therapy in cancer: identification of responders. Br J Cancer 66:1185-1187, 1992
32. Simpson WG, Heys SD, Whiting PH, et al: Acute phase proteins and recombinant IL2 therapy: Prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol 99:143-147, 1995
33. Klein B, Wijdenes J, Zhang XG, et al: Murine anti-interleukin 6 monoclonal antibody therapy in myeloma. Blood 78:1198-1204, 1991
34. Baumann H, Gauldie J: The acute phase response. Immunol Today 15:74-80, 1994
35. Gogard A, Fauchet F, Raher S, et al: Generation of monoclonal antibodies against HILDA/LIF and their use in the quantitative assay of the cytokine. Cytokine 5:16-23, 1993
36. Lu C, Vickers MF, Kerbel RS: Interleukin 6: A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 89:9215-9219, 1992
37. Mizutani Y, Bonavida B, Koishihara Y, et al: Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 55:590-596, 1995
38. Demchak PA, Mier JW, Robert NJ, et al: Interleukin 2 and high-dose cisplatin in patients with metastatic melanoma. J Clin Oncol 9:1821-1830, 1991
39. Richard JM, Gilewski TA, Ramming K, et al: Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69:427-429, 1992
40. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 alone. N Engl J Med 316:889-897, 1987
41. Blay JY, Favrot MC, Negrier S, et al: Correlation between clinical response to IL2 and sustained production of TNF. Cancer Res 50:2371-2374, 1990
42. Isacson R, Kedar E, Barak V, et al: Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin 2: Evaluation of hematologic and immunologic parameters and correlation with clinical response. Immunol Lett 33:127-134, 1992
43. Aderka D, Le J, Vilcek J: IL6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 143:3517-3524, 1989
44. Mule JJ, McIntosh JK, Jablons DM, et al: Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 171:629-636, 1990
45. Ohe Y, Podack ER, Olsen KJ, et al: Interleukin-6 cDNA transfected Lewis lung carcinoma eels show unaltered net tumour growth rate but cause weight loss and shorten survival in syngenic mice. Br J Cancer 67:939-944, 1993
46. Khayat D, Borel C, Tourani JM, et al: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11:2173-2180, 1993
47. Atkins MB, O'Boyle KR, Sosman JA, et al: Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12:1553-1560, 1994
48. Chen L, Linsley PS, Hellsröm KE: Costimulation of T cells for tumor immunity. Immunol Today 14:483-486, 1993
49. Loeffler CM, Smyth MJ, Longo DL, et al: Immunoregulation in cancer bearing hosts. J Immunol 149:949-956, 1992
50. Bataille R, Boccadoro M, Klein B, et al: C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80:733-737, 1992
51. Frank SJ, Reilmann R, Applewhite J, et al: Predictors of long-term survival in stage IV melanoma. Proc Am Soc Clin Oncol 14:411, 1995 (abstr 1302)